Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.58 |
| ▸ | RELA | Q04206 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.51 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.51 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.51 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.50 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.50 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4131672 | 0.84 | KDM4E (0.54) | NPC1RAB9ASMN1; SMN2MAPTL3MBTL1 | |
| SCHEMBL9462022 | 0.83 | ALDH1A1 (0.53) | NPC1RAB9ASMN1; SMN2MAPTNFKB1 | |
| SCHEMBL29678882 | 0.82 | RAB9A (0.57) | NPC1RAB9ASMN1; SMN2MAPTNFKB1 | |
| SCHEMBL10900818 | 0.82 | ALDH1A1 (0.64) | RAB9ASMN1; SMN2ALDH1A1KDM4ELMNA | |
| SCHEMBL30365058 | 0.81 | PDCD1 (0.71) | NPC1RAB9ASMN1; SMN2MAPTNFKB1 | |
| SCHEMBL31547621 | 0.80 | MAPT (0.57) | NPC1RAB9ASMN1; SMN2MAPTNFKB1 | |
| SCHEMBL19895199 | 0.80 | NPC1 (0.47) | NPC1RAB9ASMN1; SMN2MAPTNFKB1 | |
| SCHEMBL1920743 | 0.80 | PDCD1 (0.49) | NPC1RAB9ASMN1; SMN2MAPTNFKB1 | |
| SCHEMBL19895200 | 0.79 | RAB9A (0.49) | NPC1RAB9ASMN1; SMN2MAPTNFKB1 | |
| SCHEMBL12818210 | 0.79 | KMT2A (0.60) | NPC1RAB9AALDH1A1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-26 | — | — | US | disclosed |
| US-12168009-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-12-17 | — | — | US | disclosed |
| CN-112279808-B | Cystic fibrosis transmembrane conductance regulator modulators | 弗特克斯药品有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-112250627-B | Cystic fibrosis transmembrane conductance regulator modulators | 弗特克斯药品有限公司 | 2024-02-02 | — | — | CN | disclosed |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-07-27 | — | — | US | disclosed |
| US-11426407-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-08-30 | — | — | US | disclosed |
| US-20210052584-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-02-25 | — | — | US | disclosed |
| US-20210052584-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-02-25 | — | — | US | disclosed |
| US-5716998-A | PARTICLES COMPRISING POLYPROPYLENE RESIN AND DIAMIDE COMPOUND AS BETA-FORM NUCLEATING AGENT | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1998-02-10 | — | — | US | disclosed |
| EP-0790262-A1 | PROPYLENE-ETHYLENE COPOLYMER COMPOSITIONS AND PROCESS FOR THE PRODUCTION THEREOF | CHISSO CORPORATION (JP) | 1997-08-20 | — | — | EP | disclosed |
| EP-0790275-A1 | PREFOAMED PARTICLES OF POLYPROPYLENE RESIN AND PROCESS FOR PRODUCING THE SAME | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1997-08-20 | — | — | EP | disclosed |
| EP-0776933-A1 | Polybutene-1 resin composition and a method of accelerating the crystal transformation | NEW JAPAN CHEMICAL CO.,LTD. (JP) | 1997-06-04 | — | — | EP | disclosed |
| US-5626757-A | RESOLUTION OF ENANTIOMORPHS BY ELECTROPHORESIS AND CHROMATOGRAPHY | ADVANCED SEPARATION TECHNOLOGIES INC. (US) | 1997-05-06 | — | — | US | disclosed |
| EP-0748247-A1 | MACROCYCLIC ANTIBIOTICS AS SEPARATION AGENTS | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 1996-12-18 | — | — | EP | disclosed |
| US-5491188-A | ADDING DIAMIDE COMPOUNDS AS NUCLEATING AGENT TO PROPYLENE HOMO-, CO- AND TERPOLYMERS; FILTRATION MEMBRANES, PRINTING SHEETS | NEW JAPAN CHEMICAL CO., LTD. (JP) | 1996-02-13 | — | — | US | disclosed |
| WO-1995022390-A1 | MACROCYCLIC ANTIBIOTICS AS SEPARATION AGENTS | CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 1995-08-24 | — | — | WO | disclosed |
| EP-0632095-A2 | Porous stretched article of polypropylene-based resin and process for its preparation | NEW JAPAN CHEMICAL CO.,LTD. (JP) | 1995-01-04 | — | — | EP | disclosed |
| EP-0557721-A2 | Crystalline polypropylene resin composition and amide compounds | NEW JAPAN CHEMICAL CO.,LTD. (JP) | 1993-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11426407-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SLC26A4 | NPC1 236/4885RAB9A 888/4885SMN1; SMN2 4751/4885 |
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | NPC1 236/4885RAB9A 888/4885SMN1; SMN2 4751/4885 |
| US-20210052584-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | NPC1 236/4885RAB9A 888/4885SMN1; SMN2 4751/4885 |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | NPC1 236/4885RAB9A 888/4885SMN1; SMN2 4751/4885 |
| US-12168009-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SLC26A4 | NPC1 236/4885RAB9A 888/4885SMN1; SMN2 4751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.